ReviewFrontiers in immunology2026
Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis-driven bile duct injury and fibrosis. Biliary epithelial cells (BECs) play a central role in both bile homeostasis and immune regulation, and their metabolic and immune dysfunction is critical in PBC pathogenesis. Furthermore, systemic metabolic disturbances, such as gut dysbiosis, contribute to disease progression. This paper systematically examines the interplay between BEC metabolism-including bile acid imbalance and lipotoxicity-and immune dysregulation, such as autoantigen exposure and Th1/Th17 responses, highlighting how these interactions fuel a self-sustaining "metabolo-immune-fibrosis" cycle in PBC. Current and emerging therapies are also reviewed, emphasizing that future management should move beyond single-pathway targeting and pursue combination strategies capable of simultaneously modulating metabolic, inflammatory, and immune networks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.